ライフサイエンスコーパス: chemotherapy regimen

1 ists have control (eg, surgical technique or chemotherapy regimen).

2 a lower intensity version of the first-line chemotherapy regimen).

3 he control group; 14 matched by both age and chemotherapy regimen).

4 0 had received at least one prior metastatic chemotherapy regimen.

5 he stratification factors of age and planned chemotherapy regimen.

6 umour size, clinical stage, and prespecified chemotherapy regimen.

7 plus docetaxel is an appropriate first-line chemotherapy regimen.

8 nostic procedures and 37% involved choice of chemotherapy regimen.

9 0; n = 54) as part of an otherwise identical chemotherapy regimen.

10 during or after a first-line platinum-based chemotherapy regimen.

11 ail reminders timed to the start of each new chemotherapy regimen.

12 efinitive treatment, with no known effective chemotherapy regimen.

13 omparable with Headstart, a standard-of-care chemotherapy regimen.

14 s treatment with at least one platinum-based chemotherapy regimen.

15 aily, or placebo until there was a change of chemotherapy regimen.

16 , number of metastatic sites, and first-line chemotherapy regimen.

17 eeks or 10 mg/kg every 2 weeks, depending on chemotherapy regimen.

18 nd received at least one previous multiagent chemotherapy regimen.

19 (NSCLC) includes the use of a platinum-based chemotherapy regimen.

20 se characteristics, and myelotoxicity of the chemotherapy regimen.

21 cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen.

22 apy for locally advanced disease and optimal chemotherapy regimen.

23 atients treated prospectively with a uniform chemotherapy regimen.

24 ymphoma who previously received at least one chemotherapy regimen.

25 alignancies with this doxorubicin-containing chemotherapy regimen.

26 tive trials are needed to define the optimal chemotherapy regimen.

27 d failed one previous doxorubicin-containing chemotherapy regimen.

28 ysis to identify the most effective adjuvant chemotherapy regimen.

29 se characteristics, and myelotoxicity of the chemotherapy regimen.

30 who will receive one of the widely-accepted chemotherapy regimens.

31 and liver during treatment with 2 different chemotherapy regimens.

32 ved fluorouracil- and oxaliplatin-containing chemotherapy regimens.

33 ting the cancer plasma cell population using chemotherapy regimens.

34 ser therapy to treat OM induced by different chemotherapy regimens.

35 s a curable disease with currently available chemotherapy regimens.

36 of conventional all-trans retinoic acid plus chemotherapy regimens.

37 ies and showed no difference between the two chemotherapy regimens.

38 s failed to respond to at least two previous chemotherapy regimens.

39 y and, thus, improved efficacy over standard chemotherapy regimens.

40 be effective in cells resistant to existing chemotherapy regimens.

41 ment failure with one to two prior cytotoxic chemotherapy regimens.

42 n tube carcinoma with a maximum of two prior chemotherapy regimens.

43 mab or among patients treated with different chemotherapy regimens.

44 ve studies suggest a benefit for combination chemotherapy regimens.

45 iven a median of three (range 1-16) previous chemotherapy regimens.

46 agulation therapy, and safety with differing chemotherapy regimens.

47 uses of drugs and biologicals in anticancer chemotherapy regimens.

48 BL may be used to design "immunostimulatory" chemotherapy regimens.

49 taxane is the sequence used in most adjuvant chemotherapy regimens.

50 ated with standard or only slightly modified chemotherapy regimens.

51 lement of supportive care for many high-dose chemotherapy regimens.

52 ences in selection of breast cancer adjuvant chemotherapy regimens.

53 hout adjuvant chemotherapy, and by differing chemotherapy regimens.

54 h agents, and 47.7% had received three prior chemotherapy regimens.

55 hemotherapy, and 18 (9%) required additional chemotherapy regimens.

56 ence interval [CI] 0.33-0.71, P < .001) than chemotherapy regimens.

57 ase in dose-density and/or dose-intensity of chemotherapy regimens.

58 multimodality approaches that include newer chemotherapy regimens.

59 eloping new anticancer drugs and combination chemotherapy regimens.

60 the toxicity and deliverability of standard chemotherapy regimens.

61 nse and EFS in TNBC patients under different chemotherapy regimens.

62 egarding the use of ATR inhibitors in cancer chemotherapy regimens.

63 LMO2-driven leukemias resistant to existing chemotherapy regimens.

64 (HL) tend to be poor following conventional chemotherapy regimens.

65 C biology and in identifying best-performing chemotherapy regimens.

66 to 65% to 70% after the advent of multiagent chemotherapy regimens.

67 successfully treated with a cisplatin-based chemotherapy regimen adequate for stage.

68 The optimal chemotherapy regimen administered concurrently with preo

69 t and Bowel Project trial R-04 compared four chemotherapy regimens administered concomitantly with RT

70 duced amenorrhea varies with patient age and chemotherapy regimens administered.

71 ation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy

72 -stage regression trial with three different chemotherapy regimens, alone or in combination with the

73 with GCT who received a cisplatin-containing chemotherapy regimen and had available tumor tissue were

74 effects were related to the lymphodepleting chemotherapy regimen and included lymphopenia, neutropen

75 Treatment, defined as specific chemotherapy regimen and number of cycles, was allocated

76 questions remain about the ideal concurrent chemotherapy regimen and optimal management of patients

77 mly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per d

78 of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after

79 Both standard chemotherapy regimens and mAbs directed against ATLL tum

80 ment and recovery of bone marrow by specific chemotherapy regimens and may also enable imaging of org

81 Alternative chemotherapy regimens and neoadjuvant chemoradiation are

82 patients receiving adjuvant docetaxel-based chemotherapy regimens and occurred similarly in patients

83 Subset analyses evaluating histology, chemotherapy regimen, and incremental COX-2 expression d

84 All patients had received at least two prior chemotherapy regimens, and 17 patients had undergone pri

85 m cell transplant or two previous multiagent chemotherapy regimens, and for patients with relapsed or

86 exposure to radiation therapy, four or more chemotherapy regimens, and more than 5 days of apheresis

87 the evolution of gliomas during conventional chemotherapy regimens, and open new avenues for the sear

88 easures included: first, number and types of chemotherapy regimens, and second, frequency and timing

89 he community received less-toxic and shorter chemotherapy regimens, and those treated had fewer adver

90 ial design to define whether six cycles of a chemotherapy regimen are superior to four cycles.

91 ted with best supportive care is 2-3 months, chemotherapy regimens are associated with median surviva

92 Different adjuvant chemotherapy regimens are available for early-stage brea

93 Because anthracycline-based chemotherapy regimens are standard treatment for TNBC, w

94 Conventional intravenous chemotherapy regimens are toxic, cumbersome, and negativ

95 (EGFR) -targeted therapies and conventional chemotherapy regimens are warranted in clinical practice

96 ressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to com

97 chemoradiotherapy to 64.3 Gy, with the same chemotherapy regimen as in the induction phase.

98 e, and paclitaxel plus gemcitabine (the same chemotherapy regimen as the other group, with the additi

99 regimens derive the same benefits from newer chemotherapy regimens as younger patients but should be

100 This study confirms that all chemotherapy regimens assessed have very modest efficacy

101 In combination with standard chemotherapy regimens, bevacizumab significantly prolong

102 AAML03P1 and AAML0531 arm B, with identical chemotherapy regimens but with different toxicity report

103 Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom durable.

104 and cisplatin remain the most commonly used chemotherapy regimens, but work is ongoing to develop ne

105 re have been attempts to optimise multi-drug chemotherapy regimens by focusing on improving survival

106 min use will facilitate greater adherence to chemotherapy regimens by reducing mucositis.

107 as cytogenetic high risk, receive intensive chemotherapy (regimen C), and will only be recommended f

108 nto a 3-month adriamycin/cytoxan neoadjuvant chemotherapy regimen can predict final, postsurgical pat

109 These systemic chemotherapy regimens can also be applied both preoperat

110 Neoadjuvant radio/chemotherapy regimens can markedly improve cervical canc

111 Chart review examined chemotherapy regimens, cardiac risk factors, imaging res

112 m that the addition of rituximab to standard chemotherapy regimens (chemoimmunotherapy) improves both

113 mab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician an

114 With the data for the two chemotherapy regimens combined, the addition of bevacizu

115 d in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients rece

116 ted radiotherapy (STRT) followed by a common chemotherapy regimen consisting of eight cycles of cispl

117 y assigned 302 patients to receive induction chemotherapy regimens consisting of cytosine arabinoside

118 ession who exhibit reduced responsiveness to chemotherapy regimens containing doxorubicin.

119 dy irradiation, radiation to the gonads, and chemotherapy regimens containing high-dose alkylators ca

120 The preferred chemotherapy regimen contains a platinum agent and etopo

121 re randomly assigned to one of the following chemotherapy regimens: continuous intravenous infusional

122 rituximab (1400 mg), stratified by induction chemotherapy regimen (cyclophosphamide, doxorubicin, vin

123 Elderly patients treated with newer adjuvant chemotherapy regimens derive the same benefits from newe

124 The overall number of chemotherapy regimens did not differ significantly by st

125 ion renders cells more sensitive to standard chemotherapy regimen due to a DNA repair defect.

126 o interaction between treatment duration and chemotherapy regimen, ER/PgR, or HER2 status on RFS or O

127 Risk was raised after each common chemotherapy regimen except, based on limited numbers an

128 ast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combinatio

129 ular lymphoma by administering a preparative chemotherapy regimen followed by autologous T cells gene

130 eatment with an anthracycline-based adjuvant chemotherapy regimen followed by high-dose chemotherapy

131 d-line therapy typically includes multiagent chemotherapy regimens followed by autologous stem cell t

132 ll memory in 73 children undergoing a 2-year chemotherapy regimen for acute lymphoblastic leukemia (A

133 il (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesoph

134 arm) alone in patients receiving their first chemotherapy regimen for CLL.

135 The chemotherapy regimen for each patient was selected befor

136 ) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer.

137 n and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary

138 There is currently no standard chemotherapy regimen for patients with lymphoid malignan

139 m selection of a bladder-sparing trimodality chemotherapy regimen for patients with muscle invasive b

140 rial was designed to select a cetuximab plus chemotherapy regimen for phase III evaluation.

141 Recurrent GBM patients with < or = 1 chemotherapy regimen for progressive disease were eligib

142 There is no standard chemotherapy regimen for relapsed disease, although a fe

143 is study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pret

144 ged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chrom

145 n essential component of primary and salvage chemotherapy regimens for acute myeloid leukemia (AML).

146 ideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including

147 of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and

148 The purpose of this study was to compare two chemotherapy regimens for LGGs in children younger than

149 atment, one of the components of combination chemotherapy regimens for lymphoma.

150 from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer,

151 prior platinum; breast cancer with >/= three chemotherapy regimens for metastatic disease; pancreatic

152 C who had received no more than two previous chemotherapy regimens for mTNBC were randomly allocated

153 Standard, intravenous chemotherapy regimens for neuroendocrine tumors have bee

154 oxic effects than with alternative available chemotherapy regimens for patients with advanced melanom

155 ved upfront chemotherapy and up to two prior chemotherapy regimens for recurrent disease.

156 Doxorubicin forms the basis of chemotherapy regimens for several malignancies, includin

157 tern Europe vs or other), number of previous chemotherapy regimens for unresectable, locally advanced

158 -risk metastatic disease receive combination chemotherapy regimens from the start.

159 administration of a component of the initial chemotherapy regimen, generally the nonplatinum cytotoxi

160 urther therapies should take into account of chemotherapy regimen, genotypes of metabolizing enzymes

161 eceived at least two previous platinum-based chemotherapy regimens, had achieved complete or partial

162 requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified.

163 Current research suggests that standard chemotherapy regimens have been optimized to maximal eff

164 Platinum-doublet chemotherapy regimens have been shown to extend survival

165 Some chemotherapy regimens have been well established as firs

166 parative standard platinum-based combination chemotherapy regimens have demonstrated inferior surviva

167 ositive patients treated with newer adjuvant chemotherapy regimens have improvements in relapse-free

168 Intensive chemotherapy regimens have led to a substantial improvem

169 Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant th

170 ho had received rituximab in addition to the chemotherapy regimen (hazard ratio, 3.3; 95% CI, 1.0-14.

171 tion procedure was used, taking into account chemotherapy regimen, histology, addition or not of beva

172 se observation if scans are clear to various chemotherapy regimens, hormonal treatment, and surgery.

173 ly through the application of platinum-based chemotherapy regimens; however, clinical challenges in G

174 dy therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosp

175 afety of adding nelarabine to a BFM 86-based chemotherapy regimen in children with newly diagnosed T-

176 n added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed ad

177 ion (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objec

178 sion on or after one previous platinum-based chemotherapy regimen in the metastatic setting.

179 The use of pediatric intensive combination chemotherapy regimens in adolescents and young adults ha

180 here is little information on using standard chemotherapy regimens in AML xenografts.

181 critical importance of an adherence to oral chemotherapy regimens in attaining cure for children wit

182 ent use of non-guideline-concordant adjuvant chemotherapy regimens in black women and women with lowe

183 ized phase II trial to investigate two novel chemotherapy regimens in combination with concurrent tho

184 chieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients

185 II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer

186 coids are critical components of combination chemotherapy regimens in pediatric acute lymphoblastic l

187 AD/CVAD) or intensive (hyper-CVAD) frontline chemotherapy regimens in the pre-rituximab era.

188 metastatic NSCLC received similar numbers of chemotherapy regimens in the sample, early palliative ca

189 Most chemotherapy regimens included anthracyclines, taxanes,

190 Chemotherapy regimens included doublet therapy, single-a

191 Adjuvant chemotherapy regimens included in any of several publish

192 essed as a predictive marker in a variety of chemotherapy regimens including anthracyclines.

193 Combination chemotherapy regimens including irinotecan and oxaliplat

194 All patients who receive highly emetogenic chemotherapy regimens (including anthracycline plus cycl

195 Patients previously treated with one to two chemotherapy regimens (including one platinum-based regi

196 Systemic chemotherapy regimens, including consolidative approache

197 Combination chemotherapy regimen incorporating CD20 antibodies are c

198 erior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.

199 The extension of 'pediatric-inspired' chemotherapy regimens into young and middle-age adults h

200 This low-dose chemotherapy regimen is effective for children with EBV-

201 locally advanced cervix cancer; the optimal chemotherapy regimen is not yet defined.

202 Choosing the optimal chemotherapy regimen is still an unmet medical need for

203 spitalized cancer patients receiving current chemotherapy regimens is not known.

204 l dose administered as a low-dose metronomic chemotherapy regimen largely prevented therapy-induced s

205 posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and

206 ship has improved with current radiation and chemotherapy regimens, long-term effects have been ident

207 ilgrastim with a moderately myelosuppressive chemotherapy regimen markedly reduced febrile neutropeni

208 s with breast cancer treated with a standard chemotherapy regimen (n = 764) were enrolled in a prospe

209 mia burden prior to transplantation, salvage chemotherapy regimens need to be employed.

210 All patients received the same chemotherapy regimen of bortezomib and dexamethasone.

211 Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine

212 h cHL between 1989 and 2012 treated with the chemotherapy regimen of doxorubicin, bleomycin, vinblast

213 ts, such as the recent promising combination chemotherapy regimen of folinic acid (leucovorin), fluor

214 e nodes, we found no evidence that extending chemotherapy regimens of AC or single-agent T from four

215 opathological response to fluorouracil-based chemotherapy regimens, of which the FAD binding protein

216 e necessary to determine the impact of newer chemotherapy regimens on survival.

217 s had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combin

218 Independent of preoperative chemotherapy regimen, optimal morphologic response is su

219 T) and recurrence after at least one salvage chemotherapy regimen or with anaplastic histology Wilms'

220 Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in t

221 ittle is known regarding the use of specific chemotherapy regimens or treatment duration.

222 These patients may benefit from intensified chemotherapy regimens or, ideally, should enroll in clin

223 t to receive chemotherapy, 12 (2%) chose one chemotherapy regimen over another, six (1%) considered n

224 ared with 0% of patients receiving two prior chemotherapy regimens (P < .01).

225 ce status, histology, and number of previous chemotherapy regimens, patients were randomly assigned (

226 platin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyw

227 75 mg/m(2) of body surface area) or the same chemotherapy regimen plus bevacizumab 7.5 mg per kg body

228 expansion in the use of improved combination chemotherapy regimens plus or minus biologics, to render

229 Solid tumor chemotherapy regimens pose a risk for hepatitis B virus

230 rubicin, bleomycin, vinblastine, dacarbazine chemotherapy regimen, prescribed for nearly all patients

231 375 mg/m(2) on days -19 and -12 and the same chemotherapy regimen (R-BEAM).

232 in a 3:2:2:2 ratio, stratified by centre and chemotherapy regimen: radical radiotherapy alone (n=233)

233 ts had been given a median of three previous chemotherapy regimens (range 1-5 in cohort 1, and 2-4 in

234 ents had received a median of three previous chemotherapy regimens (range, one to seven), and 73% had

235 s, it is demonstrated that age, the specific chemotherapy regimen received, and tamoxifen use impact

236 ng cancer (NSCLC) who had at least two prior chemotherapy regimens received gefitinib 250 or 500 mg/d

237 The median number of prior chemotherapy regimens received was four.

238 The chemotherapy regimens resulted in similar EFS and overal

239 The addition of cetuximab to these chemotherapy regimens results in an overall survival adv

240 Comparison of the three chemotherapy regimens revealed 84% of patients treated w

241 plus rituximab (BR) vs a standard rituximab-chemotherapy regimen (rituximab plus cyclophosphamide, d

242 nhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician.

243 ognostic factors-age, trial, number of prior chemotherapy regimens, sex, and race/ethnicity-were eval

244 In patients with hepatic CRM, the chemotherapy regimen should be carefully considered beca

245 Decisions regarding adjuvant chemotherapy regimens should take into account baseline

246 desmoid tumors remains a challenge, but new chemotherapy regimens show some promise in treating this

247 Both chemotherapy regimens significantly improved LFS compare

248 to select low-risk patients for abbreviated chemotherapy regimens similar to those used in our study

249 diagnosis and after a median of 2 different chemotherapy regimens, somatic mosaic PPM1D mutations in

250 sing permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and s

251 ) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, le

252 Chemotherapy regimens that combine anthracyclines and ta

253 One possibility is that standard chemotherapy regimens that include CYP3A substrates may

254 We compared two chemotherapy regimens that included methotrexate (MTX),

255 These pages report on new chemotherapy regimens that sharply reduce the risk of re

256 nephropathy treated with a bortezomib-based chemotherapy regimen, the use of high-cutoff hemodialysi

257 both irinotecan-based and oxaliplatin-based chemotherapy regimens, the combination of BV and FU/LV w

258 rimental treatment consisted of one of three chemotherapy regimens: the low-dose leucovorin plus FU (

259 The optimal chemotherapy regimen to use with radiotherapy in stage I

260 nts were treated with intensive conditioning chemotherapy regimens to destroy the autoreactive immune

261 s had received between two and five previous chemotherapy regimens (two or more for advanced disease)

262 that trial has been difficult because of the chemotherapy regimen used (methotrexate with/without ifo

263 The 2 most common chemotherapy regimens used concurrently with thoracic ra

264 Because intensive chemotherapy regimens used in most childhood cancers are

265 The intensive chemotherapy regimens used to treat acute myeloid leukae

266 Like classical chemotherapy regimens used to treat cancer, targeted the

267 Cooperative group studies have led to chemotherapy regimens using the same drugs (vincristine,

268 dition to their planned cisplatin-containing chemotherapy regimen, using permuted blocks of four.

269 The chemotherapy regimens varied, but the only CRs were obse

270 safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as secon

271 mab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for fi

272 ibodies directed against CD20 into frontline chemotherapy regimens warrants investigation.

273 A busulfan-based chemotherapy regimen was used for bone marrow transplant

274 Addition of nelarabine to a BFM 86-based chemotherapy regimen was well tolerated and produced enc

275 age was 57 years and median number of prior chemotherapy regimens was five.

276 patients treated, the median number of prior chemotherapy regimens was four (range, one to 11 regimen

277 as 51 months, and the median number of prior chemotherapy regimens was three.

278 The median number of prior chemotherapy regimens was two, and 74% of all patients r

279 king radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of do

280 static cancer (N = 312) following at least 1 chemotherapy regimen were followed prospectively until d

281 refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio o

282 s who had received no more than one previous chemotherapy regimen were randomly assigned on a 2:1 sch

283 ish, and who were scheduled to receive a new chemotherapy regimen were recruited from eight instituti

284 open-label randomised arm in which high-dose chemotherapy regimens were compared.

285 gynecologic malignancies beginning standard chemotherapy regimens were enrolled between April and Se

286 who had relapsed after two or more previous chemotherapy regimens were randomly assigned (1:1) by an

287 Key steps in the development of modern chemotherapy regimens were the demonstrations in clinica

288 All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients rece

289 ent neuroblastoma (only one prior aggressive chemotherapy regimen) were randomly assigned to daily 5-

290 es for oxaliplatin-based or irinotecan-based chemotherapy regimens, were randomly assigned in a 1:1 r

291 e induction or fewer or received an adjuvant chemotherapy regimen, who had adequate organ function, a

292 serous ovarian cancer, treated with multiple chemotherapy regimens, who exhibited regression of some

293 ed afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line

294 erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-s

295 s compared with the etoposide plus cisplatin chemotherapy regimen with thoracic radiation therapy in

296 in patients with breast cancer who received chemotherapy regimens with low-to-intermediate risk of i

297 ned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cy

298 ive to historical controls who received this chemotherapy regimen without bevacizumab.

299 ant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes.

300 ncer and whether adding bevacizumab to these chemotherapy regimens would increase the rates of pathol